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Abstract
Asthma and chronic obstructive pulmonary disease (COPD) are common chronic airway diseases. Overlap in the clinical features of
these 2 diseases is observed in many cases, and thus, the concept of asthma–COPD overlap (ACO) has recently been proposed.
However, the deﬁnition of ACO and the clinical signiﬁcance remains to be determined.
We evaluated the prevalence and risk of acute exacerbation in ACO among Korean COPD patients as deﬁned bymodiﬁed Spanish
criteria and American Thoracic Society (ATS) Roundtable criteria.
The prevalence of ACOwas 47.7% (660/1383) by modiﬁed Spanish criteria and 1.9% (26/1383) by ATS Roundtable criteria. ACO,
regardless of criteria, did not signiﬁcant affect the exacerbation risk during at least 1-year follow-up period.
Substantial discrepancies were found in the prevalence and outcome of ACO according to different diagnostic criteria, which
would compromise implementation of ACO before the deﬁnition is established.
Abbreviations: %pred =%predicted, ACO = asthma–COPD overlap, ATS = American Thoracic Society, BDR = bronchodilator
response, CAT = COPD Assessment Test, CI = conﬁdence interval, COPD = chronic obstructive pulmonary disease, FEV1 = forced
expiratory volume in 1 second, FVC = forced vital capacity, HR = hazard ratio, ICS/LABA = inhaled corticosteroid/long-acting beta 2
agonist, IgE = immunoglobulin E, IRR = incidence rate ratio, KOCOSS = Korean COPD subtype study, LAMA = long-acting
muscarinic antagonist, mMRC = modiﬁed medical research council dyspnea.
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Recently published guidelines for asthma[1] and chronic
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1asthma–COPD overlap (ACO), which is a condition having
clinical features of both asthma and COPD.
Typically, asthma and COPD can be easily distinguished from
each other. Asthma is a chronic airway disease that typically
develops in childhood and is often accompanied by allergic
conditions.[1] Patients with asthma have type 2 inﬂammation
promoted by helper T cells and eosinophils[3] and usually present
variable and episodic symptoms.[4] COPD is also a chronic
airway disease that is related to the smoking history of an
individual.[4] Airway inﬂammation predominantly caused by
neutrophils and type 1 T cells is observed in COPD,[3,5] leading to
persistent and progressive symptoms.[4]
However, both asthma and COPD commonly occur world-
wide,[6,7] and patients with these diseases present with similar
respiratory symptoms related to airway obstruction. Advanced
cases of COPD often have variable airﬂow obstruction, whereas
those of asthma may be related to persistent airﬂow obstruc-
tion.[8] Thus, ACO was introduced some years ago,[9,10] and
several studies report that patients with ACO have different
clinical characteristics and courses.[9,11–13] Because treatment for
ACO may be different from that for typical COPD or
asthma,[14,15] the early and appropriate diagnosis of ACO may
contribute to an improvement in the clinical outcomes of
patients with ACO.
However, the acceptance of this condition as a unique disease
entity in clinical practice is problematic and requires further
study.[4,8,16] For example, issues that require investigation
include the numbers of COPD patients diagnosed with ACO,
and whether these patients have a clinical course and treatment
reversibility distinguishable from those of patients with COPD.
Most importantly, however, the deﬁnition of ACO has not
been established although several diagnostic criteria exist.[17]
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prognosis, and treatment reversibility will vary according to
different diagnostic criteria,[18] little research has been conducted
on this issue. Therefore, in this prospective cohort study, we
investigated the prevalence and risk of exacerbation according to
2 distinct ACO diagnostic criteria: modiﬁed Spanish criteria[11]
and American Thoracic Society (ATS) Roundtable criteria.[19]2. Methods
We analyzed data from KOCOSS (Korean COPD subtype study
NCT02800499), which is a prospective and observational study
enrolling COPD patients from 28 hospitals in Korea.[20] All
patients enrolled KOCOSS were provided written informed
consent. COPD was deﬁned as a post-bronchodilator forced
expiratory volume in 1second (FEV1)/forced vital capacity (FVC)
<0.7 in patients aged >40 years and with >10 pack-years of
smoking history.
ACO is deﬁned based on either themodiﬁed Spanish criteria (at
least 1 major criterion or at least 2 minor criteria in COPD
patients)[11] or ATS Roundtable criteria (all 3 major criteria and
at least 1 minor criterion).[19] The modiﬁed Spanish criteria are as
follows: major criteria: bronchodilator response (BDR) to
salbutamol >400mL and 15% and previous history of asthma;
minor criteria: serum immunoglobulin E (IgE) >100IU/mL or
history of atopy , blood eosinophils>5%, and 2 separate BDR>
12% and 200mL. When the patient fulﬁlls at least 1 major or 2
minor criteria, they are diagnosed as ACO. ATS Roundtable are
as follows: major criteria: persistent airﬂow limitation and aged
≥40 years, smoking >10 pack-years or equivalent air pollution
exposure, and documented history of asthma before 40 years of
age or BDR > 400mL; minor criteria: documented history of
atopy or allergic rhinitis, 2 separate BDR > 12% and 200mL,
and blood eosinophil count of ≥300/mL. We ﬁrst calculated the
prevalence of ACO according to these criteria. Next, the ACO
and non-ACO groups were compared. Chi-square tests or
Fisher’s exact tests were applied for categorical variables, and
Student’s t tests orMann–Whitney tests were used for continuous
variables. Third, we investigated the risk of exacerbation in each
group. Exacerbation was deﬁned as COPD symptom aggravation
requiring systemic corticosteroids, antibiotics, or hospitalization.
Time to initial exacerbation was analyzed using the Cox
proportional hazard model. Incidence rates were analyzed using
the negative binomial regression model adjusted by covariates,
including age, sex, body mass index (BMI), total symptom score
for dyspnea (St. George’s Respiratory Questionnaire [SGRQ],
COPD Assessment Test [CAT], and mMRC [the modiﬁed
medical research council dyspnea scale]), initial FEV1 (%), use of
inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA),
and use of long-acting muscarinic antagonist (LAMA). P< .05
was considered statistically signiﬁcant. All statistical analyses
were performed using STATA version 14.2 (StataCorp, College
Station, TX).
This study was approved by the Institutional Review Board
(IRB) of each hospital (Gacheon University Gil Medical Center,
Gangnam Severance Hospital, Kyung Hee University Hospital
at Gangdong, Sungkyunkwan University Kangbuk Samsung
Hospital, Kangwon National University Hospital, Konkuk
University Hospital, Konkuk University Chungju Hospital,
Kyungpook National University Hospital, Gyeongsang Na-
tional University Hospital, Korea University Anam Hospital,
Dongguk University Gyeongju Hospital, Dong-A University
Hospital, Pusan National University Hospital, The Catholic2University of Korea Bucheon St. Mary’s Hospital, Soon-
chunhyang University Hospital Bucheon, Seoul National
University Bundang Hospital, Bundang CHA Hospital, Eulji
General Hospital, Seoul National University Hospital, Seoul
Metropolitan Government Seoul National University Boramae
Medical Center, Samsung Medical Center, The Catholic
University of Korea Seoul St. Mary’s Hospital, Asan Medical
Center, The Catholic University of Korea St. Paul’s Hospital,
The Catholic University of Korea St. Vincent’s Hospital,
Severance Hospital, Soonchunhyang University Seoul Hospital,
Ajou University Hospital, The Catholic University of Korea
Yeouido St. Mary’s Hospital, Yeungnam University Medical
Center, Ulsan University Hospital, Wonju Severance Christian
Hospital, The Catholic University of Korea Uijeongbu St.
Mary’s Hospital, Ewha Womans University Mokdong Hospi-
tal, Incheon St. Mary’s Hospital, Inha University Hospital,
Ilsan Paik Hospital, Chonnam National University Hospital,
Chonbuk National University Hospital, Jeju National Univer-
sity Hospital, Soonchunhyang University Hospital Cheonan,
Hallym University Gangnam Sacred Heart Hospital, Hallym
University Kangdong Sacred Heart Hospital, Hallym Universi-
ty Dongtan Sacred Heart Hospital, Hallym University
Chuncheon Sacred Heart Hospital, Hallym University Sacred
Heart Hospital, Hanyang University Guri Hospital). Also, we
obtained the approval of patient’s medical records from each
center and maintained conﬁdentiality.3. Results
In total, 1383 COPD patients were included, of which 660
(47.7%) met the modiﬁed Spanish criteria and 26 (1.9%) met the
ATS Roundtable criteria. Among the patients who fulﬁlled the
ATS Roundtable criteria, age was signiﬁcantly lower for ACO
than for non-ACO patients (64.8±1.7 vs 69.5±0.2, P< .01).
Furthermore, the change in FEV1 following salbutamol treatment
(BDR, %) was higher in ACO than in non-ACO patients (19.1±
2.9 vs 7.1±0.2, P< .01). Other demographic characteristics—
SGRQ, CAT, mMRC, spirometry measurements, and previous
history of acute exacerbation–were similar between ACO and
non-ACO groups. (Table 1)
The prevalence of ACO as deﬁned by modiﬁed Spanish criteria
and ATS Roundtable criteria was 47.7% and 1.9%, respectively.
Six hundred ﬁfteen patients (46.5% among those for whom
records were available) had a history of asthma but only 33
(2.4%) patients reported asthma documentation before 40 years
of age (adjusted to 27 [2.0%] showing BDR > 400mL). Because
participants in the KOCOSS study underwent annual spirometry
testing, there were no cases with 2 separate tests at baseline and
thus no patients were classiﬁed as meeting the criterion ”two
separate BDR > 12% and 200mL” (Table 2).
Patients with ACO according to the modiﬁed Spanish criteria
(adjusted hazard ration [HR], 0.73; 95% conﬁdence interval
[CI]=0.50–1.08; adjusted incidence rate ratio [IRR], 0.82; 95%
CI=0.55–1.23) and ATS Roundtable criteria (adjusted HR,
0.63; 95% CI=0.19–2.10; adjusted IRR 0.46; 95% CI=0.11–
1.90) did not affect exacerbation risk (Table 3).4. Discussion
Our study showed a substantial difference in the prevalence of
ACOaccording to the 2 diagnostic criteria in COPDpatients. The
prevalence of ACO was 47.7% when the modiﬁed Spanish
criteria were applied, but only 1.9% on ATS Roundtable criteria.
Table 1
Baseline characteristics of patients with and without diagnosis for asthma-chronic obstructive pulmonary disease overlap.
Modiﬁed Spanish criteria ATS Roundtable criteria
Variables Total (n=1383) ACO (n=660) Non-ACO (n=476) P value ACO (n=26) Non-ACO (n=1338) P value
Age 69.3±7.6 69.7±0.3 69.0±0.4 .13 64.8±1.7 69.5±0.2 <.01
Sex (male) 1264 (92.7%) 606 (91.8%) 445 (93.5%) .29 26 (100%) 1238 (92.5%) .25
Pack-year 41.6±26.7 41.3±1.1 42.7±1.3 .42 39.5±5.4 41.6±0.7 .69
BMI, kg/m2 22.8±3.4 22.7±0.1 23.0±0.2 .14 23.1±0.6 22.8±0.1 .61
FEV1 (L) 1.5±0.5 1.4±0.02 1.4±0.02 .65 1.5±0.1 1.5±0.01 .77
FEV1% pred 54.7±17.5 53.9±0.7 54.9±0.8 .35 52.2±2.9 54,9±0.5 .43
FVC (L) 3.04±0.79 3.0±0.03 3.1±0.04 .11 3.1±0.2 3.0±0.02 .91
FVC % pred 80.9±17.7 80.1±0.7 82.2±0.8 .05 76.6±3.5 81.1±0.5 .21
FEV1/FVC % pred 61.0±42.0 58.2±1.0 63.4±4.4 .21 57.0±6.6 61.1±1.8 .81
BDR % 7.3±0.3 8.3±0.4 7.2±0.4 .07 19.1±2.9 7.1±0.2 <.01
mMRC 1.5±0.9 1.5±0.04 1.5±0.04 .87 1.3±0.2 1.5±0.03 .21
SGRQ total 34.9±19.0 34.6±0.8 35.1±0.9 .67 32.9±4.4 34.8±0.5 .62
CAT total 15.9±7.9 15.6±0.3 16.1± .4 .32 16.8±1.5 15.8±0.2 .52
Total exacerbation in the past year (/yr) 2.1±2.1 2.0±0.1 2.2±0.2 .42 1.4±0.4 2.1±0.1 .42
Severe exacerbation in the past year (/yr) 0.7±1.1 0.8±0.1 0.6±0.1 .06 0.3±0.2 0.7±0.1 .31
% pred=% predicted, ACO=Asthma-chronic obstructive pulmonary disease overlap, ATS=American thoracic society, BDR=bronchodilator response, BMI=body mass index, CAT total=COPD Assessment
Test total, FEV1= forced expiratory volume in one second, FVC= forced vital capacity, mMRC=The modiﬁed medical research council dyspnea scale, SGRQ total=St George’s Respiratory Questionnaire total.
Table 2
Patients fulﬁlling the modiﬁed Spanish and American thoracic
society Roundtable criteria for asthma-chronic obstructive pul-
monary disease overlap.
Modiﬁed Spanish criteria Meeting criterion (n)
Major (1) Previous history of asthma 615 (46.5%)
Major (2) BDR > 15% and 400 mL 27 (2.0%)
Minor (1) Serum IgE>100 IU, or history of atopy 270 (74.0%)
Minor (2) 2 separate BDR>12% and 200 mL 0
Minor (3) Blood eosinophils>5% 206 (18.4%)
ACOS 660 (47.7%)
ATS Roundtable criteria
Major (1) Post-BDR FEV1/FVC<0.7 and age>40 years 1383 (100%)
Major (2) Smoking>10 PY or air pollution≥10 PY 1383 (100%)
Major (3) Asthma<40 years or BDR>400mL in FEV1 60 (4.4%)
Minor (1) History of atopy or allergic rhinitis 165 (12.5%)
Minor (2) Two separate BDR>12% and 200mL 0
Minor (3) Blood eosinophil count>300/mL 277 (24.8%)
ACO 26 (1.9%)
ACO= asthma-chronic obstructive pulmonary disease overlap, ATS=American thoracic society,
BDR=bronchodilator response, FEV1= forced expiratory volume in 1 second, FVC= forced vital
capacity, IgE= immunoglobulin E, PY=pack-year.
Table 3
The risk of moderate-to-severe exacerbation of chronic obstructiv
pulmonary disease criteria.
Time to ﬁrst moderate-to-severe exacerbation
Crude HR (95% CI)
ACO according to modiﬁed Spanish criteria 0.75 (0.54–1.03)
ACO according to ATS Roundtable criteria 0.49 (0.18–1.34)
Incidence rate of moderate-to-severe exacerbation
Crude IRR (95% CI)
ACO according to modiﬁed Spanish criteria 0.84 (0.57–1.24)
ACO according to ATS Roundtable criteria 0.43 (0.11–1.72)
ACO= asthma-chronic obstructive pulmonary disease overlap, ATS=American thoracic society, CI= co
∗
Models adjusted for age, sex, body mass index, total St. George’s Respiratory Questionnaire score, initial
use of long-acting muscarinic antagonist.
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3ACO, regardless of criteria, did not affect the exacerbation risk
during the follow-up period.
According to previous reports,[13,19,21–24] the prevalence of
ACO among COPD patients ranged from 3.3% to 54.6%.
However, no study to date has compared prevalence according to
different criteria. In addition, no study has reported the
prevalence of ACO according to ATS Roundtable criteria among
COPD patients. This is the ﬁrst report, to our knowledge, to
compare 2 diagnostic criteria of ACO, and the ﬁrst on the
prevalence of ACO according to ATS Roundtable criteria among
COPD patients from a prospective cohort.
The substantial discrepancy in the prevalence of ACO in our
study could have been affected by several factors. First, around
half of the patients with COPD in our study reported a history of
asthma, which resulted in a high percentage fulﬁlling the ﬁrst
major criterion of the modiﬁed Spanish criteria. While previous
studies [12,24–26] reported that many COPD patients had a history
of asthma, the percentage of those with such a history among our
COPD patients was relatively high. This may be due to the fact
that cheonsik, the Korean word for asthma, could have been
confused with COPD, heart failure, or chronic respiratory
conditions in Korea, and the condition is thought to be part of the
”normal” aging process and is frequently accepted as part ofe pulmonary disease according to asthma-chronic obstructive
P value Adjusted HR (95% CI)
∗
P value
.079 0.73 (0.50–1.08) .11
.162 0.63 (0.19–2.10) .449
P value Adjusted IRR (95% CI)
∗
P value
.391 0.82 (0.55–1.23) .335
.230 0.46 (0.11–1.90) .282
nﬁdence interval, HR=hazard ratio, IRR= incidence rate ratio.
forced expiratory volume in 1 second (%), use of inhaled corticosteroid/long-acting beta 2 agonist, and
[24,26]
Song et al. Medicine (2018) 97:36 Medicinegrowing old. The possibility that cheonsik is not the speciﬁc
term for asthma can be illustrated by the fact that the percentage of
patients with documented asthma history before 40 years of age
was relatively small, resulting in the low percentage of major ATS
roundtable criteria recorded. Our results show the weakness of
diagnosis based on self-reported history. In fact, the revisedGlobal
Initiative for Asthma guidelines state the importance of objective
measurement of variable expiratory airﬂow limitation, in
combination with symptoms.[1] In addition, only a small
proportion of COPD patients had bronchodilator reversibility
>400mL, which contributed to the low rate of fulﬁllment for the
major ATS Roundtable criteria. These ﬁndings correspond to
previous studies, which reported that 4.7% (39/831) of COPD
patients hadBDR>15%and400mL,[11] and1.17%of thosewith
mild COPD had BDR> 15%.[12] In fact, this cut-off value (>400
mL) used to determine the presence of asthma does not have any
supporting evidence. Both modiﬁed Spanish[11] and ATS Round-
table criteria[19] deﬁne minor ACO criteria with BDR>12%, 200
mL on 2 separate visits, but the basis for this is also unclear.
Most previous studies have shown worse outcomes in ACO
patients compared with non-ACO COPD patients.[9,12,13,23] On
the other hand, a CHAIN cohort study reported enhanced
survival in the ACO group.[11] Our study did not ﬁnd any
statistically signiﬁcant effects of ACOon exacerbation risk. These
differences may depend on the differences in the deﬁnition criteria
for ACO used in studies. However, interestingly, even when the
target studies were conﬁned to those applying modiﬁed Spanish
criteria as criteria for ACO[11,23] including the current study,
different results were observed. It suggests ACO might not be a
good prognostic factor. Further studies are needed.
Our study has several limitations. First, data were missing on
serum IgE, eosinophil count, and age at diagnosis of asthma.
However, we found no signiﬁcant difference between patients
with and without missing data regarding baseline clinical
characteristics. Second, the number of patients diagnosed with
ACO according to ATS Roundtable criteria was low, and only 5
patients experienced acute exacerbation; this could have resulted
in low statistical power.
In conclusion, the prevalence of ACO and clinical outcomes
varied markedly according to diagnostic criteria. This may be due
to thedependenceon self-reportedhistory in thediagnostic criteria,
which suggests the requirement of objective measurement-based
diagnosis. This substantial discrepancy would hinder the imple-
mentation of ACO before determination of the deﬁnition.Author contributions
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